Clinical Trial Update: Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-1) [Phase 3]

View source ↗

Summary

Phase 3 safety and efficacy study of a gene therapy for critical limb ischemia has completed the trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Critical Limb Ischemia
• Peripheral Artery Disease

Drugs mentioned

• NL003-CLI-III-1

Snippet

Sponsor: Beijing Northland Biotech. Co., Ltd. | Conditions: Arterial Occlusive Disease, Ischemia | Phase 3 | Status: COMPLETED